Anti psychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia - A systematic review

被引:153
作者
Gao, Keming [1 ]
Kemp, David E. [1 ]
Ganocy, Stephen J. [1 ]
Gajwani, Prashant [1 ]
Xia, Guohua [1 ]
Calabrese, Joseph R. [1 ]
机构
[1] Case Western Reserve Univ, Sch Med, Dept Psychiat,Bipolar Disorder Res Ctr, Mood Disorders Program,Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA
关键词
D O I
10.1097/JCP.0b013e318166c4d5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: Newer atypical antipsychotics have been reported to cause a lower incidence of extrapyramidal side effects (EPS) than conventional agents. This review is to compare antipsychotic-induced EPS relative to placebo in bipolar disorder (BPD) and schizophrenia. Methods: English-language literature cited in Medline was searched with terms antipsychotics, placebo-controlled trial, and bipolar disorder or schizophrenia and then with antipsychotic (generic/brand name), safety, akathisia, EPS, or anticholinergic use, bipolar mania/depression, BPD, or schizophrenia, and randomized clinical trial. Randomized, double-blind, placebo-controlled, monotherapy studies with comparable doses in both BPD and schizophrenia were included. Absolute risk increase and number needed to treat to harm (NNTH) for akathisia, overall EPS, and anticholinergic use relative to placebo were estimated. Results: Eleven trials in mania, 4 in bipolar depression, and 8 in schizophrenia were included. Haloperidol significantly increased the risk for akathisia, overall EPS, and anticholinergic use in both mania and schizophrenia, with a larger magnitude in mania, an NNTH for akathisia of 4 versus 7, EPS of 3 versus 5, and anticholinergic use of 2 versus 4, respectively Among atypical antipsychotics, only ziprasidone significantly increased the risk for overall EPS and anticholinergic use in both mania and schizophrenia, again with larger differences in mania, an NNTH for overall EPS of I 1 versus 19, and anticholinergic use of 5 versus 9. In addition, risks were significantly increased for overall EPS (NNTH = 5) and anticholinergic use (NNTH = 5) in risperidone-treated mania, akathisia in aripiprazole-treated mania (NNTH = 9) and bipolar depression (NNTH = 5), and overall EPS (NNTH = 19) in quetiapine-treated bipolar depression. Conclusions: Bipolar patients, especially in depression, were more vulnerable to having acute antipsychotic-induced movement disorders than those with schizophrenia.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 52 条
[1]   Confidence intervals for the number needed to treat [J].
Altman, DG .
BRITISH MEDICAL JOURNAL, 1998, 317 (7168) :1309-1312
[2]  
[Anonymous], 2004, J CLIN PSYCHIAT, V65, P120
[3]   Multiple fixed doses of ''Seroquel'' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo [J].
Arvanitis, LA ;
Miller, BG ;
Borison, RL ;
Pitts, WM ;
Sharif, ZA ;
Hamner, MB ;
Herz, MI ;
True, JE ;
Velligan, D ;
Knesevich, MA ;
Small, J ;
Steinbook, R ;
Hertzman, M ;
Keck, PE ;
Newcomer, JW ;
Grace, J ;
Rotrosen, J ;
Tandon, R ;
Dott, SG ;
Ferguson, JM ;
Addington, DEN ;
MacEwan, GW ;
Nair, VNP ;
Shriqui, CL ;
Williams, R ;
Daniel, DG ;
Shehi, GM ;
Patterson, WM ;
Merideth, CH .
BIOLOGICAL PSYCHIATRY, 1997, 42 (04) :233-246
[4]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[5]   Dimensionality, responsiveness and standardization of the Bech-Rafaelsen Mania Scale in the ultra-short therapy with antipsychotics in patients with severe manic episodes [J].
Bech, P ;
Baastrup, PC ;
de Bleeker, E ;
Ropert, R .
ACTA PSYCHIATRICA SCANDINAVICA, 2001, 104 (01) :25-30
[6]   A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression [J].
Calabrese, JR ;
Keck, PE ;
Macfadden, W ;
Minkwitz, M ;
Ketter, TA ;
Weisler, RH ;
Cutler, AJ ;
McCoy, R ;
Wilson, E ;
Mullen, J .
AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (07) :1351-1360
[7]   Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials [J].
Cavazzoni, PA ;
Berg, PH ;
Kryzhanovskaya, LA ;
Briggs, SD ;
Roddy, TE ;
Tohen, M ;
Kane, JM .
JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (01) :107-113
[8]  
CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P25
[9]   Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies [J].
Correll, CU ;
Leucht, S ;
Kane, JM .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (03) :414-425
[10]   Inference by eye - Confidence intervals and how to read pictures of data [J].
Cumming, G ;
Finch, S .
AMERICAN PSYCHOLOGIST, 2005, 60 (02) :170-180